Mizuho initiated coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a report published on Monday, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $26.00 price target on the biotechnology company’s stock.
A number of other brokerages have also weighed in on BOLD. Raymond James Financial restated a hold rating on shares of Audentes Therapeutics in a report on Thursday, January 4th. William Blair restated a buy rating on shares of Audentes Therapeutics in a report on Friday, January 5th. BMO Capital Markets set a $44.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a report on Friday, January 5th. Zacks Investment Research lowered shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Monday, January 22nd. Finally, Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an outperform rating in a report on Thursday, January 4th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $34.00.
Shares of Audentes Therapeutics (NASDAQ BOLD) traded up $1.47 on Monday, hitting $34.29. 203,100 shares of the stock were exchanged, compared to its average volume of 538,700. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.
In related news, Director Louis G. Lange sold 18,000 shares of Audentes Therapeutics stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Suyash Prasad sold 8,000 shares of Audentes Therapeutics stock in a transaction on Friday, December 1st. The stock was sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. 47.30% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. Teachers Advisors LLC raised its stake in Audentes Therapeutics by 12.7% during the 4th quarter. Teachers Advisors LLC now owns 30,347 shares of the biotechnology company’s stock worth $948,000 after acquiring an additional 3,421 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Audentes Therapeutics during the 3rd quarter worth $143,000. Nationwide Fund Advisors raised its stake in Audentes Therapeutics by 288.9% during the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 6,384 shares in the last quarter. Wells Fargo & Company MN raised its stake in Audentes Therapeutics by 86.1% during the 3rd quarter. Wells Fargo & Company MN now owns 14,414 shares of the biotechnology company’s stock worth $404,000 after acquiring an additional 6,667 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new position in Audentes Therapeutics during the 4th quarter worth $208,000. Hedge funds and other institutional investors own 64.94% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/16/audentes-therapeutics-bold-coverage-initiated-by-analysts-at-mizuho.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.